As weight loss medications containing active ingredients like semaglutide continue to define a new chapter in metabolic ...

Inclusion of weight loss drugs on insurer formularies is a meaningful step towards expanding access. But having a product ...

According to Mochi Health, more than half of its patients lose at least 10% of their body weight within the first six months, ...

Beginning July 1, millions of Americans on Medicare will have access to GLP-1 weight-loss drugs for just $50 a month. Under ...

What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss. By Mark Miller Millions of older Americans may have access for the first time to obesity drugs ...

Hers is a telehealth platform for women that offers access to GLP-1 weight loss medications. The service provides FDA-approved drugs, online provider communication, and a holistic approach through its ...

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs A new weight-loss drug has helped participants in a sizable trial lose much more ...

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 pounds, in a late-stage clinical trial, the drugmaker said in a news ...

Rapid Weight Loss Beats Slow and Steady in New Clinical Trial By HealthDay Staff HealthDay ReporterMONDAY, May 18, 2026 (HealthDay News) — When it comes to weight loss, is slow and steady really the ...

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...

People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said. By Gina Kolata and Rebecca Robbins An experimental shot helped participants ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...